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Abstract
Objective: To establish whether diabetic ketoacidosis (DKA) or HbA1c at onset is
associated with year-three HbA1c in children with type 1 diabetes (T1D).
Methods: Children with T1D from the SWEET registry, diagnosed <18 years, with
documented clinical presentation, HbA1c at onset and follow-up were included. Par-
ticipants were categorized according to T1D onset: (a) DKA (DKA with coma, DKA
without coma, no DKA); (b) HbA1c at onset (low [<10%], medium [10 to <12%],
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high [≥12%]). To adjust for demographics, linear regression was applied with interac-
tion terms for DKA and HbA1c at onset groups (adjusted means with 95% CI). Associ-
ation between year-three HbA1c and both HbA1c and presentation at onset was
analyzed (Vuong test).
Results: Among 1420 children (54% males; median age at onset 9.1 years [Q1;Q3:
5.8;12.2]), 6% of children experienced DKA with coma, 37% DKA without coma, and
57% no DKA. Year-three HbA1c was lower in the low compared to high HbA1c at
onset group, both in the DKA without coma (7.1% [6.8;7.4] vs 7.6% [7.5;7.8], P = .03)
and in the no DKA group (7.4% [7.2;7.5] vs 7.8% [7.6;7.9], P = .01), without differ-
ences between low and medium HbA1c at onset groups. Year-three HbA1c did not
differ among HbA1c at onset groups in the DKA with coma group. HbA1c at onset as
an explanatory variable was more closely associated with year-three HbA1c com-
pared to presentation at onset groups (P = .02).
Conclusions: Year-three HbA1c is more closely related to HbA1c than to DKA at
onset; earlier hyperglycemia detection might be crucial to improving year-three
HbA1c.
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1 | INTRODUCTION
Diabetic ketoacidosis (DKA) is a life-threatening complication of new-
onset type 1 diabetes (T1D) in children and has a wide range of inci-
dence worldwide, varying from 13% to 80%.1,2 The incidence of DKA
is moderate and stable in Germany (21.1%),3 Austria (37.2%),4 USA
(30%),5 UK (25%),6 New Zealand (27%),7 and Poland (25%).8 Compara-
tively, the rates are highest in France (43.9%)9 and Brazil (42%)10 and
reach alarming levels in the third world, Africa (71.1%-88%).11 The
lowest rates are in some select groups from first world countries,
namely under longitudinal follow-up in Sweden (16%), Ontario,
Canada (18.6%), Finland (19.4%), and Denmark (17.9%).12,13 It is well-
known that there is a negative correlation between background inci-
dence of T1D and the frequency of DKA at onset.14 However, even
within similar geographical regions, DKA rates can vary, as shown in
the Italian population under 15 years of age: the frequency of DKA
was 41.9%, but much lower in Sardinia (23.6%), comparable to that
reported in countries with a high incidence of T1D, due to the high
level of suspicion in this region.15 Lower residual β-cell function and
poorer glycemic control during the following 1 to 2 years have been
shown in children with DKA at presentation.13,16 What remains to be
further examined is whether it is chronic hyperglycemia (glycated
hemoglobin [HbA1c]) or DKA at diagnosis that is the most important
variable determining the following metabolic control. Viswanathan
et al (2011) showed that HbA1c levels at onset might predict future
metabolic control, however, the study was relatively small (120 chil-
dren).17 Similar results were partly confirmed by Nilsson et al (2017)
showing that high HbA1c at onset was associated with high HbA1c
during follow-up.18 A retrospective analysis from the UK showed that
tracking of HbA1c values occurs at all levels of HbA1c, such that chil-
dren who reach HbA1c target early in the course of the disease are
more likely to continue with low HbA1c levels.19 Hofer et al (2014)
similarly confirmed in an Austrian/German multicenter setting the evi-
dence for long-term tracking of metabolic control from childhood until
adulthood.20
SWEET (Better control in Pediatric and Adolescent diabeteS:
Working to crEate CEnTers of Reference) comprises a large multina-
tional consortium of pediatric diabetes clinics worldwide collecting
diabetes-related information on patients in a standardized data-
base.21,22 This study then represents a unique opportunity to evaluate
a heterogeneous group of children with T1D worldwide and to exam-
ine the relationships between HbA1c and DKA at onset and subse-
quent metabolic control during the first and the third year after
diagnosis and whether third-year HbA1c is more closely associated to
DKA or HbA1c at onset.
2 | RESEARCH DESIGN AND METHODS
2.1 | Data sources and subjects
This analysis is based on data from the international, prospective, mul-
ticenter, standardized diabetes registry SWEET. Currently, 78 centers
from five continents (47 from Europe) are included. All contributing
centers meet specific entry criteria and are compliant with the Inter-
national Society for Pediatric and Adolescent Diabetes (ISPAD) clinical
practice guidelines and the national database security and ethical
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requirements.22-24 As of September 2018, the SWEET database
included 49 224 patients with 554 487 visits.
This is a multi-centered, register-based, cross-sectional observa-
tional, descriptive study from the SWEET database. Subjects with
T1D, diagnosed before 18 years, with documented clinical presenta-
tion and HbA1c at onset and follow-up data available during the first
and the third year after diagnosis were included. T1D was defined
using the ISPAD clinical presentation guidelines.25 Centers of the
Asian/African region were excluded because data might not be repre-
sentative due to the low number of patients (<20 subjects). The full
study cohort, which included all patients with reported presentation
at onset, consisted of 2932 youths with T1D treated in 29 centers
from 17 European countries and six countries outside Europe
(Figure S1). In a sub-analysis, children with documented HbA1c at
onset were analyzed (n = 1420).
2.2 | Outcome variables
The SWEET dataset considers five categories of presentation at T1D
onset: DKA with coma, DKA without coma, ketosis, hyperglycemia, or
by screening. The most severe category which applied to the patient
was used. DKA is defined according to the ISPAD guidelines (pH < 7.3
or bicarbonate <15 mmol/L).26 Coma was defined clinically (Pediatric
Glasgow Coma Scale [PGCS]). In this analysis, presentation at onset
was classified as DKA with coma, DKA without coma or no DKA. Meta-
bolic control was assessed by HbA1c, which was measured locally in
each center. In order to adjust for differences among laboratories, a
multiple of the mean (MOM) method was used, to mathematically
standardize HbA1c values to the reference range of the Diabetes
Control and Complications Trial (DCCT, 21-43 mmol/mol
[4.05-6.05%]).27 Any use of insulin pump was defined as pump treat-
ment. Body mass index (BMI) was calculated as weight in kilogram
divided by height squared in meters. BMI SD score (BMI z-score) was
calculated using the World Health Organization (WHO) reference.28
DKA beyond onset was defined according to the ISPAD guidelines
and severe hypoglycemia (SH) was defined as an event that led to
alterations in consciousness and required the assistance of another
person.26,29 Data was aggregated per patient during the first and third
year after T1D diagnosis. Onset was defined as the first 10 days after
T1D manifestation.
Four geographic regions were defined based on a combination of
location and number of centers: (a) Northern Europe: Austria, Czech
Republic, France, Denmark, Germany, Lithuania, Luxembourg, Nether-
lands, Poland, Sweden; (b) Southern Europe: Bulgaria, Croatia, Greece,
Hungary, Portugal, Serbia, Spain; (c) Australia/New Zealand; and
(d) America/Canada: US, Canada, Argentina, Costa Rica.
Eligible patients were divided into three groups based on age at
onset: <6 years, 6 to <12 years, 12 to ≤18 years. In the sub-cohort of
patients with documented HbA1c at onset, HbA1c at onset was
divided into three groups: low < 10% (<86 mmol/mol); medium 10 to
<12% (86 to <108 mmol/mol); and high ≥ 12% (≥ 108 mmol/mol).
2.3 | Statistical analysis
Data were summarized using median with quartiles for continuous
variables or proportion for binary variables. Wilcoxon, Kruskal-Wallis
or χ2-tests were used to analyze differences among groups. P values
were corrected by Bonferroni-Holm method to adjust for multiple
testing.
Among the presentation at onset groups, curves of HbA1c per
month during the first year after T1D onset were estimated using
locally weighted scatterplot smoothing (LOESS). Analyzing differences
in HbA1c among presentation at onset groups for months 4 to 12 after
diagnosis, a regression model taking into account multiple measure-
ments was applied, which was adjusted for age at onset, gender and
region.
Analyzing the third year after diagnosis, linear and logistic
regression models were applied to adjust for confounders. In order
to address variation among diabetes centers, region was entered as
a fixed covariate. Moreover, models were adjusted for age at onset
groups and gender. A model for the year-three HbA1c with addi-
tional adjustment for BMI-SDS and insulin dose was implemented.
An additional model with an interaction term between presentation
at onset group and HbA1c at onset group was applied. To adjust for
multiple comparisons, Tukey-Kramer test was used. Results are pres-
ented as adjusted means with 95% confidence intervals (CI). Vuong
test was employed in order to compare a model with HbA1c at onset
groups versus a model with presentation at onset groups, to ascer-
tain which one as explanatory variable was closer to the true distri-
bution of the data of year-three HbA1c. Vuong test is probabilistic,
based on H0 (both models are equally close to the true distribution
of data) against the alternative hypothesis that one model is
closer.30
A two-sided P value < .05 was defined as statistically significant.
All analyses were performed with Statistical Analysis Software 9.4
(SAS, SAS Institute Inc. Cary, North Carolina).
3 | RESULTS
The entire study cohort included 2932 children (53% male) with 1942
patients from Europe, 246 from Australia/New Zealand and 744 from
America/Canada. Table 1 includes demographics and clinical parame-
ters among the full cohort, the sub-cohort with documented HbA1c
at onset (n = 1420), and for boys and girls separately.
3.1 | DKA with coma, DKA without coma, and no
DKA groups
In the full cohort, 16% of children had DKA with coma at T1D onset,
27% DKA without coma and 57% no DKA. Table 2 includes baseline
demographics and clinical parameters among presentation at onset
groups.
There was no difference in clinical presentation at onset groups
between boys and girls. Overall there was no difference in age at
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onset groups distribution by the presentation at onset; however, DKA
with coma tended to be more common at T1D onset in children aged
6-12 years, while DKA without coma tended to be more common in
children below 6 years of age and T1D with no DKA in subjects
between 12 and 18 years of age (Table 2).
There was variation in regions distribution across the DKA groups
(P < .01), (Table 2). While in Northern Europe DKA with coma was only
present in 4.7% of children and the largest proportion of children pres-
ented with no DKA (60.7%), in the American/Canadian region DKA with
coma was more frequent (40%) and fewer children (46.3%) presented
with no DKA. In Southern Europe and Australia/New Zealand the dis-
tribution among presentation at onset groups was comparable to the
full study cohort.
3.2 | First year after diagnosis
HbA1c was higher in the DKA with coma group compared to the other
groups throughout the first year of diabetes (both P < .01), even after
adjustment for demographics (Figure 1). HbA1c was not significantly
different between DKA without coma and no DKA groups. HbA1c nadir
value was reached simultaneously in the three groups during the
fourth month after diagnosis, with the lowest value in the group with
no DKA. Afterwards, HbA1c increased in all three groups.
3.3 | Third year after diagnosis
Year-three HbA1c and clinical data is presented in Table 2 according
to presentation at onset groups and the results of clinical variables
adjusted for demographics (age at onset, gender and region) are pres-
ented in Table S1.
3.3.1 | Association of DKA at onset-year-three
HbA1c
The highest year-three HbA1c was observed in DKA with coma group
compared to both the DKA without coma group and the no DKA group
TABLE 1 Demographics and clinical parameters of the study cohort and the sub-cohort of children with documented HbA1c at onseta




N 2932 1554 1378 1420 767 653
Age (years) at onset 9.2 [5.7;12.1] 9.4 [5.6;12.4] 8.9 [5.8;11.6] 9.1 [5.8;12.2] 9.5 [5.9;12.5] 8.7 [5.7;11.6]
0-<6 years (%) 27 27 27 27 26 28
6-<12 years (%) 48 45 51 47 44 49
12-≤18 years (%) 25 28 23 26 30 23
Males (%) 53 54
Northern Europe (%) 48 48 46 70 70 69
Southern Europe (%) 19 19 19 24 24 24
Australia/New Zealand (%) 8 8 9 0 0 0
America/Canada (%) 25 25 26 6 6 7
Presentation at onset
DKA with coma (%) 16 16 17 6 6 7
DKA without coma (%) 27 27 27 37 37 38
No DKA (%) 57 57 56 57 57 55
Clinical parameters at
onset
HbA1c (%) at onset 11.5 [10.1; 13.3] 11.2 [10.0; 12.9] 12.0 [10.3; 13.7]
BMI-SDS at onset −0.32 [−1.17; 0.65] −0.26 [−1.22; 0.67] −0.37 [−1.06; 0.61]
Clinical parameters during
third year after onset
Year-three HbA1c (%) 7.7 [6.9; 8.5] 7.6 [6.9; 8.5] 7.7 [7.0; 8.6] 7.4 [6.8; 8.1] 7.3 [6.7; 8.1] 7.4 [6.8; 8.1]
Year-three BMI-SDS 0.60 [−0.07; 1.27] 0.56 [−0.12; 1.30] 0.64 [0.00; 1.23] 0.56 [−0.10; 1.17] 0.48 [−0-16; 1.23] 0.65 [−0-01; 1.16]
Therapy
Insulin pump first year
(%)
27 27 27 23 23 24
Insulin pump third year
(%)
40 39 42 37 36 38
aDescriptive data were summarized using median [Q1;Q3] for continuous variables or proportion (%) for binary variable.
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(P < .01) (Table 2). Even after adjustment for demographics (Table S1)
and additional adjustment for pump use similar results were found.
After further adjustment for BMI-SDS and daily insulin dose, similar
results were detected.
3.3.2 | Association of age groups-year-three HbA1c
Year-three HbA1c, adjusted for gender and region, was evaluated
among the three age-groups (Figure S2). In the youngest age group
TABLE 2 Demographics and clinical parameters during the third year among presentation at onset groupsa
Variable DKA with coma DKA without coma No DKA P value
N 483 792 1657
Males (%) 16.1 27.0 56.9 <.01
Females (%) 16.9 26.9 56.2
Age (years) at onset 9.1 [5.8; 11.7] 9.2 [5.2; 12.1] 9.2 [5.9; 12.2] n.s.
0-<6 years (%) 16.5 29.7 53.8
6-<12 years (%) 17.8 25.5 56.7
12-≤18 years (%) 13.9 27.1 59.0
Northern Europe (%) 4.7 34.6 60.7 <.01
Southern Europe (%) 15.7 23.9 60.4
Australia/New Zealand (%) 13.8 31.3 54.9
America/Canada (%) 40.0 13.7 46.3
Clinical parameters during the third year
HbA1c (%) 8.4 [7.4; 9.5] 7.4 [6.8; 8.2] 7.6 [6.9; 8.4] <.01
BMI-SDS 0.59 [−0.13; 1.28] 0.75 [0.06; 1.33] 0.54 [−0.10; 1.24] <.01
Pump use (%) 45.4 40.0 39.1 n.s.
DKA on follow-up (%) 3.5 1.3 1.8 n.s.
SH on follow-up (%) 3.9 1.5 3.4 n.s.
aDescriptive data were summarized using median [Q1;Q3] for continuous variables or proportion (%) for binary variables. A two-sided P value < .05 was
defined as statistically significant.
Abbreviations: n.s., not significant.
F IGURE 1 HbA1c (%) by month during the first year after T1D diagnosis in each presentation at onset group. Curves of HbA1c per month
were estimated using locally weighted scatterplot smoothing (LOESS). Line and shaded area: Loess fit and 95% CI
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(<6 years), HbA1c was higher in the DKA with coma group than in the
DKA without coma and no DKA groups (both P < .01). In children aged
6 to <12 years at onset, higher HbA1c was found in the DKA with
coma group compared to the DKA without coma group (P < .01). No
significant difference was observed for the 12 to 18 years age group
at onset.
3.3.3 | Association of region-year-three HbA1c
Year-three HbA1c, adjusted for age at onset and gender among each
region (Figure S3), was studied in order to compare year-three HbA1c
among presentation at onset groups in each region separately. In
Northern Europe, year-three HbA1c was better in children who experi-
enced DKA with coma compared to children with DKA without coma
and with no DKA (both P < .01). At the opposite, in America and
Canada, the highest year-three HbA1c was reached by children who
had DKA with coma compared to children with DKA without coma
(P < .01) and with no DKA (P < .01). In children from Southern Europe
and from Australia/New Zealand, no significant differences were found.
Pump use was 27% of children during the first year, increasing to
40% during the third year (Table 1), without differences among the
presentation at onset groups (Table 2), even after adjustment for
demographics (Table S1).
BMI-SDS during the third year was higher in patients who pres-
ented DKA without coma at T1D onset compared to subjects with no
DKA (P < .01) (Table 2) and this difference was maintained after
adjusting for demographics (Table S1).
The frequency of acute complications was low during the third
year: DKA was observed in 2% of children and SH in 3%, without sig-
nificant differences among the three presentation at onset groups
(Table 2). However, when results were adjusted for demographics, SH
was lower among the DKA without coma group compared to the DKA
with coma and no DKA groups (Table S1).
3.4 | Sub-analysis: Sub-cohort with documented
HbA1c at onset
In the sub-cohort of subjects with documented HbA1c at onset, 1420
subjects (54% male) were analyzed, including 994 from Northern
Europe, 341 from Southern Europe, and 85 from America/Canada.
Subjects with documented HbA1c at onset and the entire study
cohort were clinically similar. In the sub-cohort, 6% of children pres-
ented DKA with coma at T1D manifestation, 37% DKA without coma
and 57% presented no DKA.
3.4.1 | Analyzing presentation at onset groups
All results are adjusted for demographics and regions. HbA1c at onset
was similar in children experiencing DKA with coma (HbA1c 12.2%
[11.7;12.7]) and DKA without coma (HbA1c 12.1% [11.9;12.3]), while
in children with no DKA lower HbA1c at onset was found (HbA1c
11.2% [11;11.4], P < .01).
No relevant differences were found in year-three HbA1c among
the three presentations at onset groups (Figure 2A). Similar results
were found when adjusted for HbA1c at onset and even when addi-
tionally adjusted for pump use.
3.4.2 | Analyzing HbA1c at onset groups: low
HbA1c < 10% (<86 mmol/mol); medium HbA1c
10-<12% (86-<108 mmol/mol); high HbA1c ≥ 12%
(≥108 mmol/mol)
All results are adjusted for demographics and regions. Year-three
HbA1c was lower (7.4% [7.3;7.5]) in low HbA1c at onset group
F IGURE 2 Year-three HbA1c (%) in
the sub-cohort with documented HbA1c
at onset, among presentation at onset, A,
and HbA1c at onset groups, B, adjusted
for age at onset, gender, and region.
n.s. = not significant. Linear regression
models adjusted for age at onset, gender
and region were applied. A two-sided P-
value ‘0.05 was defined as statistically
significant
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compared to high HbA1c at onset group (7.7% [7.6;7.8], P < .01). No
differences in metabolic control during the third year were detected
between children in medium HbA1c at onset group (7.5% [7.4;7.6])
and both groups high or low HbA1c at onset (Figure 2B). Even after
adjustment for pump treatment, we recognized the same association.
3.4.3 | Interaction between presentation and HbA1c
at onset groups
Year-three HbA1c was lower in the low HbA1c at onset group com-
pared to high HbA1c at onset group both in the DKA without coma
group (P = .03) and in the no DKA group (P = .01), without differences
between low and medium HbA1c at onset groups (Figure 3). No signif-
icant differences in year-three HbA1c were identified among the DKA
with coma group (P = 1). Results were adjusted for regions, age at
onset and gender.
Comparing the models HbA1c at onset groups versus presentation
at onset groups, HbA1c at onset as explanatory variable was closer to
the true distribution of the year-three HbA1c data (vuong test,
P = .02), showing a closer association between HbA1c at onset groups
and year-three HbA1c than between presentation at onset groups
and year-three HbA1c.
4 | DISCUSSION
The international, multicenter SWEET registry provided the first and
unique opportunity to investigate the association between DKA at
onset, HbA1c at onset and 3 years metabolic control in a heteroge-
neous, multinational cohort of children with T1D. In the full study
cohort, we found that more than half of the children were diagnosed
without DKA at onset, but the proportion of children with DKA at
onset (43%) is still too high worldwide, suggesting that T1D is not
diagnosed early enough and in particular we observed an impressively
high rate of DKA with coma (16%). Children who experienced DKA
with coma at diagnosis presented with the highest HbA1c during the
first year after diagnosis and highest year-three HbA1c, compared to
children with DKA without coma and no DKA. Similar results were
found after adjustment for demographics and neither pump use mod-
ulated year-three HbA1c. Thus, we could speculate that DKA with
coma is related to higher year-three HbA1c, but analyzing the sub-
cohort of patients with both presentation at onset and HbA1c at
onset documented, we detected that year-three HbA1c was not sig-
nificantly different based on T1D presentation. On the other hand,
looking at the interaction between HbA1c and presentation at onset
groups, we found that year-three HbA1c is more closely related to
the levels of HbA1c at onset and therefore to chronic, sustained
hyperglycemia and long-term glycemic trend and fluctuations, than to
the different T1D presentation. This is particularly true in case of DKA
without coma and no DKA at T1D onset. The presence of DKA with
coma itself seems to be independently related to a higher year-three
HbA1c since it could be a clue of long-lasting hyperglycemia and
severe insulin deficiency, not promptly recognized. The clinical pres-
ence of coma is associated with a delay of diagnosis and therefore of
treatment and thus with a sustained and durable hyperglycemia and
moreover it is usually associated with a severe acidosis, even if pH at
T1D onset is not a documented parameter in the SWEET dataset. Our
results do not support the hypothesis that the presence of DKA at
onset could act as a spring resulting in better long-term metabolic
control, as it frightens families and they pay more attention to their
diabetes. An exception was observed in Northern Europe, where the
F IGURE 3 Results of the interaction
between presentation at onset and
HbA1c at onset model in the sub-cohort
with documented HbA1c at onset,
adjusted for age at onset, gender, and
region. Linear regression model with
interaction term presentation at onset
group and HbA1c at onset group adjusted
for age at onset, gender and region was
applied. A two-sided P-value ‘0.05 was
defined as statistically significant
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lowest year-three HbA1c was found in the DKA with coma group. This
could be related to the low prevalence of coma at T1D onset and a
more intensive insulin treatment and education in these countries.
In the United States, 30% to 46% of children newly diagnosed
with T1D experience DKA, one third severe DKA (pH <7.1). More-
over, a persistent negative correlation between DKA at diagnosis and
glycemic control was described previously.16 Duca et al (2017)
showed how HbA1c in children with severe DKA at onset tracked
1.4% higher than children without DKA, independently of demo-
graphic and socioeconomic factors.16 The study based on Dan-
DiabKids (2013) showed that DKA was present at T1D manifestation
in 17.9% of children and that 9.6% of children had moderate-severe
DKA, which was associated with poor long term metabolic control.13
Recently, Shalitin et al (2018) showed that DKA at diagnosis was
present in 39.3% of patients and was associated with less favorable
long-term glycemic control, as assessed by HbA1c and the rate of sub-
sequent DKA episodes.31
In this study, we did not find any significant difference in the dis-
tribution of DKA in the three age groups, even if some studies report
DKA at onset is more common in younger children, due to delayed
symptoms recognition. Cherubini et al (2016) reported that in Italy
50% of children under 5 years and 60.7% under 2 years of age had
DKA at diagnosis,15 which is in line with data from the DanDiabKids
registry.13 In the present study cohort, younger children (<6 years)
with DKA with coma at onset had worse third-year HbA1c compared
to both children with DKA without coma and no DKA. Interestingly,
children with age at onset ≥12 years showed the worst metabolic
control regardless the type of presentation at onset, maybe due to the
challenge of diabetes management during adolescence.
Considering year-three HbA1c among different regions, in North-
ern Europe a better HbA1c was achieved in children with DKA with
coma at onset, compared to children with DKA without coma and with
no DKA. At the opposite, in America and Canada, the worst metabolic
control was detected in children who experienced DKA with coma. It
could be speculated that the high T1D incidence and awareness in
North European countries1 are responsible for the low frequency of
presentation with DKA and coma confirmed in this study and the
small number of patients with DKA at onset could make it easier to
fine-tune tailored intensive insulin therapy and develop continuous
education. On the other hand, in America/Canada, the difference in
year-three HbA1c among the three presentation at onset groups is
largest and inverse compared to Northern Europe. These results could
be explained by the fact that in rural areas in America/Canada
patients must travel long distance to the nearest hospital and that the
rural areas are very dependent on urban areas for health care.32 Fox
et al (2018) recently reported that children traveling more than 2 hours
to attend a tertiary T1D clinic had significantly higher mean HbA1c.33
Younger age, ethnic minority, lower family income and lack of health
insurance were identified as major risk factors for DKA at T1D onset.14
Thus, social and ethic differences could justify higher rate of DKA at
onset and worse year-three Hba1c in America/Canada.
The Pediatric Diabetes Consortium T1D new onset (Neon) study
assessed clinical outcomes in 857 children treated at seven US
diabetes center from the time of diagnosis (33% DKA).34 HbA1c grad-
ually increased in all groups, in line with what we observed in the pre-
sent study, with worse metabolic control in children with DKA with
coma at onset. The concept of “metabolic tracking” highlights the
importance of striving for optimal control soon after T1D diagnosis,
which may lead to better control in the long term.19,20 Our study sug-
gests that “metabolic tracking” could start very early, even before T1D
diagnosis, from the very beginning of chronic hyperglycemia, recog-
nizing a closer association between HbA1c at onset and year-three
HbA1c, compared to the presence of DKA at onset and confirming
that year-three HbA1c is higher in children with HbA1c ≥ 12% at T1D
onset. The importance of HbA1c at disease onset is not well-known
and current studies either include few patients or have short follow-
up time and none is based on multicenter, international data. Some
authors highlighted the role of metabolic memory, suggesting that
pre-diagnosis exposure to elevated glucose levels has a bearing on
subsequent outcome.35,36 Future research is needed to establish why
children with high HbA1c values at diagnosis continue to have worse
metabolic control and if this is related to pathophysiological or genetic
issues. Our results on the relationship between clinical presentation at
onset and later metabolic control are based on a biological model.
However psycho-social/family factors might also be a reason for del-
ayed diagnosis (and presentation with DKA) and have an impact on
future care, resulting in higher HbA1c values. Future studies should
focus on this alternative model in order to understand the impact of
education and social support, and, on the other hand, of advanced
technology and intensive education.
The current study has inherent strengths and limitations. The main
strengths of the study are the large sample size, the highly heteroge-
neous, international population, a worldwide dataset and the SWEET
data quality control. One limitation of the present study might be that
HbA1c was not measured in a central laboratory, however, to reduce
variation between laboratories, HbA1c levels were mathematically
standardized. Moreover,T1D onset data is not complete enough in
the SWEET dataset and HbA1c at onset was available for 48% of chil-
dren and therefore some selection bias cannot be excluded. Some
socioeconomic and demographic factors have not been considered in
the study because they are not available in the SWEET database.
Treatment at T1D onset could be different between centers and
countries and also the hospitalization length and the level of initial
education provided by nurses, dietitians and pediatric diabetologists
could vary. We did not take into account how intensive were the ini-
tial T1D treatment and education.
In conclusion, in this heterogeneous, multinational cohort of chil-
dren considered year-three HbA1c was more closely associated with
HbA1c at onset compared to clinical presentation (DKA) at onset.
While children who experienced DKA at onset can achieve a good
metabolic control, patients with high HbA1c at onset continue to have
poor metabolic control as a group. Coma itself is also associated with
subsequent poor metabolic control. These results emphasize the
importance of identifying from the very beginning of T1D a subset of
children (eg, those with HbA1c at onset ≥12% and those with DKA
and coma, especially if younger) at major risk of future poor metabolic
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control, in order to implement intensive education and recent techno-
logical advances. Early detection of T1D, preventing a high HbA1c at
onset as well as DKA at onset with coma, is crucial to improving year-
three HbA1c.
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